Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Emory University
Headquarters: Atlanta, GA, United States of America
Website: http://www.emory.edu
Year Founded: 1836
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Feb 13, 2025
Politics, Policy & Law
Ex-COVID ‘testing czar’ Giroir rejoins HHS
Former acting FDA commissioner, Coronavirus Task Force member to serve as unpaid adviser to RFK Jr.
BioCentury | Dec 19, 2024
Discovery & Translation
Science Spotlight: Platelets as targeted protein degraders
BioCentury’s roundup of translational innovations also includes ribonucleoproteins delivery and fine-tuning TCR specificity
BioCentury | Dec 13, 2024
Discovery & Translation
Science Spotlight: snoRNA control of protein secretion, plus dual agonists for obesity
BioCentury’s roundup of translational innovations also includes an Arkuda-J&J granulin gene therapy
BioCentury | Oct 31, 2024
Emerging Company Profile
IHP: Creating an EpiPen for sickle cell disease
Company aims to keep patients out of hospital with a dual-mechanism rescue treatment to prevent vaso-occlusive crises
BioCentury | Oct 9, 2024
Distillery Therapeutics
LNP-delivered Cas13 targeting viral NS5 protein for Dengue fever
BioCentury | May 17, 2024
Product Development
Vectorized antibodies are taking gene therapy beyond rare disease
ASGCT presentations showcase cancers, infectious diseases and chronic inflammatory conditions as potential applications of vectorized antibodies
BioCentury | May 8, 2024
Emerging Company Profile
Avicenna: Using machine learning to skip the hit-to-lead phase
Seeded by DCVC Bio, Avicenna’s machine learning tech is designed to find a clinical candidate in a haystack of theoretical compounds
BioCentury | Nov 22, 2023
Emerging Company Profile
Sunbird: blood-based diagnostics via exosomes and proteases
Singapore-based Sunbird hopes to roll out its exosome-based Alzheimer’s test in 2025
BioCentury | Sep 30, 2023
Finance
Sept. 29 Quick Takes: Adlai Nortye sinks after NASDAQ listing
Plus: NASH play Madrigal raises $500M, and updates from Regeneron, Thymmune, Harvard Medical School and more
BioCentury | Sep 20, 2023
Discovery & Translation
Driving translational science, a conversation with Dennis Liotta
How changing the model for science funding to include investing in development could speed biomedical progress
Items per page:
1 - 10 of 325